Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Equity Income (2016 - 2025)

Historic Equity Income for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Q3 2025 value amounting to $6000.0.

  • Lineage Cell Therapeutics' Equity Income rose 20000.0% to $6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12000.0, marking a year-over-year increase of 14444.44%. This contributed to the annual value of -$8000.0 for FY2024, which is 9545.45% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Equity Income of $6000.0 as of Q3 2025, which was up 20000.0% from -$2000.0 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Equity Income high stood at $40000.0 for Q1 2023, and its period low was -$517000.0 during Q4 2022.
  • Its 4-year average for Equity Income is -$71923.1, with a median of -$6000.0 in 2023.
  • Over the last 5 years, Lineage Cell Therapeutics' Equity Income had its largest YoY gain of 31666.67% in 2024, and its largest YoY loss of 11250.0% in 2024.
  • Over the past 4 years, Lineage Cell Therapeutics' Equity Income (Quarter) stood at -$517000.0 in 2022, then surged by 98.84% to -$6000.0 in 2023, then surged by 316.67% to $13000.0 in 2024, then tumbled by 53.85% to $6000.0 in 2025.
  • Its Equity Income was $6000.0 in Q3 2025, compared to -$2000.0 in Q2 2025 and -$5000.0 in Q1 2025.